These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 9635675)

  • 1. Ret oncogene activation in papillary thyroid carcinoma: prevalence and implication on the histological parameters.
    Lam AK; Montone KT; Nolan KA; Livolsi VA
    Hum Pathol; 1998 Jun; 29(6):565-8. PubMed ID: 9635675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids.
    Powell DJ; Russell J; Nibu K; Li G; Rhee E; Liao M; Goldstein M; Keane WM; Santoro M; Fusco A; Rothstein JL
    Cancer Res; 1998 Dec; 58(23):5523-8. PubMed ID: 9850089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RET/PTC activation in hyalinizing trabecular tumors of the thyroid.
    Papotti M; Volante M; Giuliano A; Fassina A; Fusco A; Bussolati G; Santoro M; Chiappetta G
    Am J Surg Pathol; 2000 Dec; 24(12):1615-21. PubMed ID: 11117781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of a novel type of RET rearrangement (PTC5) in thyroid carcinomas after Chernobyl and analysis of the involved RET-fused gene RFG5.
    Klugbauer S; Demidchik EP; Lengfelder E; Rabes HM
    Cancer Res; 1998 Jan; 58(2):198-203. PubMed ID: 9443391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of RET in follicular cell-derived tumors of the thyroid gland: prevalence and implication of morphological type.
    Inaba M; Umemura S; Satoh H; Abe Y; Kurokawa K; Sakai H; Osamura RY
    Pathol Int; 2003 Mar; 53(3):146-53. PubMed ID: 12608895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes.
    Tallini G; Santoro M; Helie M; Carlomagno F; Salvatore G; Chiappetta G; Carcangiu ML; Fusco A
    Clin Cancer Res; 1998 Feb; 4(2):287-94. PubMed ID: 9516913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical localisation of RET and p53 mutant protein of thyroid lesions in a North-Eastern Malaysian population and its prognostic implications.
    Omar E; Madhavan M; Othman NH
    Pathology; 2004 Apr; 36(2):152-9. PubMed ID: 15203751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RET oncogene activation in papillary thyroid carcinoma.
    Tallini G; Asa SL
    Adv Anat Pathol; 2001 Nov; 8(6):345-54. PubMed ID: 11707626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High prevalence of RET tyrosine kinase activation in Mexican patients with papillary thyroid carcinomas.
    Martínez I; Mantilla A; Medrano ME; Hernández R; Hernández DM; Lazos M; Santiago H; González B; Hidalgo A; Salcedo M
    Endocr Pathol; 2001; 12(2):113-23. PubMed ID: 11579677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The RET proto-oncogene in medullary and papillary thyroid carcinoma. Molecular features, pathophysiology and clinical implications.
    Komminoth P
    Virchows Arch; 1997 Jul; 431(1):1-9. PubMed ID: 9247627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RET receptor expression in thyroid follicular epithelial cell-derived tumors.
    Bunone G; Uggeri M; Mondellini P; Pierotti MA; Bongarzone I
    Cancer Res; 2000 Jun; 60(11):2845-9. PubMed ID: 10850426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of RET oncogene activation in human papillary thyroid carcinomas by in situ hybridisation.
    Fabien N; Paulin C; Santoro M; Berger N; Grieco M; Galvain D; Barbier Y; Dubois PM; Fusco A
    Br J Cancer; 1992 Dec; 66(6):1094-8. PubMed ID: 1457350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of RET/PTC oncogene activation and clonality in thyroid nodules with incomplete morphological evidence of papillary carcinoma: a search for the early precursors of papillary cancer.
    Fusco A; Chiappetta G; Hui P; Garcia-Rostan G; Golden L; Kinder BK; Dillon DA; Giuliano A; Cirafici AM; Santoro M; Rosai J; Tallini G
    Am J Pathol; 2002 Jun; 160(6):2157-67. PubMed ID: 12057919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical diagnosis of papillary thyroid carcinoma.
    Cheung CC; Ezzat S; Freeman JL; Rosen IB; Asa SL
    Mod Pathol; 2001 Apr; 14(4):338-42. PubMed ID: 11301350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sporadic ret-rearranged papillary carcinoma of the thyroid: a subset of slow growing, less aggressive thyroid neoplasms?
    Soares P; Fonseca E; Wynford-Thomas D; Sobrinho-Simões M
    J Pathol; 1998 May; 185(1):71-8. PubMed ID: 9713362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis of papillary thyroid carcinoma is facilitated by using an RT-PCR approach on laser-microdissected archival material to detect RET oncogene activation.
    Lahr G; Stich M; Schütze K; Blümel P; Pösl H; Nathrath WB
    Pathobiology; 2000; 68(4-5):218-26. PubMed ID: 11279350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype.
    Santoro M; Carlomagno F; Hay ID; Herrmann MA; Grieco M; Melillo R; Pierotti MA; Bongarzone I; Della Porta G; Berger N
    J Clin Invest; 1992 May; 89(5):1517-22. PubMed ID: 1569189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RET activation and clinicopathologic features in poorly differentiated thyroid tumors.
    Santoro M; Papotti M; Chiappetta G; Garcia-Rostan G; Volante M; Johnson C; Camp RL; Pentimalli F; Monaco C; Herrero A; Carcangiu ML; Fusco A; Tallini G
    J Clin Endocrinol Metab; 2002 Jan; 87(1):370-9. PubMed ID: 11788678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RET protein expression has no prognostic impact on the long-term outcome of papillary thyroid carcinoma.
    Basolo F; Molinaro E; Agate L; Pinchera A; Pollina L; Chiappetta G; Monaco C; Santoro M; Fusco A; Miccoli P; Elisei R; Capezzone M; Pacini F
    Eur J Endocrinol; 2001 Nov; 145(5):599-604. PubMed ID: 11720878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
    Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
    Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.